Skip to main content
TLPH
NASDAQ Life Sciences

Nafamostat Gains Ground: 75% Enrollment in NEPHRO CRRT and Favorable KDIGO Guidelines

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.39
Mkt Cap
$72.66M
52W Low
$0.397
52W High
$1.57
52W Position info
250% above low
Off High info
11% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

TLPH has more than doubled off its 52-week low of $0.397.

Summary

Talphera announced 75% enrollment in its NEPHRO CRRT study, positive KDIGO guideline changes for nafamostat, and a 21% larger market estimate, alongside Q2 financial results showing a $4.3 million net loss.


Key Events · Product Development and Regulatory · TLPH

  • NEPHRO CRRT Study 75% Enrolled

    The registrational study of nafamostat is 75% enrolled and expected to complete enrollment this year, keeping the company on track for potential FDA submission.

  • KDIGO Guidelines Favor Nafamostat

    The draft 2026 KDIGO guidelines now list nafamostat as an acceptable regional anticoagulant during CRRT, a positive change from previous guidelines that could expand its commercial opportunity.

  • Market Opportunity Expanded

    Updated market research estimates approximately 200,000 annual U.S. CRRT procedures in 2027, a 21% increase over prior estimates, suggesting a larger addressable market for nafamostat.

  • Financial Position

    Cash and investments totaled $17.1 million as of June 30, 2026, with a Q2 net loss of $4.3 million. The company regained Nasdaq compliance with the $1 bid price rule.


Analysis · TLPH · Life Sciences

A significant boost for Talphera's lead product candidate, nafamostat, comes from the draft 2026 KDIGO guidelines, which now list it as an acceptable CRRT anticoagulant. The NEPHRO CRRT study is 75% enrolled and expected to complete this year, while updated market research shows a 21% larger U.S. market than previously estimated. These developments strengthen the commercial case for nafamostat, though the company still faces a going concern warning and limited cash runway.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TLPH was trading at $1.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.7M. The 52-week trading range was $0.40 to $1.57. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLPH - Latest Insights

TLPH
Nov 12, 2026, 5:11 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $1.02
Real-time Price: $0.880 info
Change: -$0.140 (-14%) info
Market Cap: $45.723M info
TLPH
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.03
Real-time Price: $0.880 info
Change: -$0.150 (-15%) info
Market Cap: $45.723M info
TLPH
Nov 12, 2026, 4:01 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.04
Real-time Price: $0.880 info
Change: -$0.155 (-15%) info
Market Cap: $45.723M info
TLPH
Aug 12, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.40
Real-time Price: $0.880 info
Change: -$0.520 (-37%) info
Market Cap: $45.723M info
TLPH
Jun 23, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.02
Real-time Price: $0.880 info
Change: -$0.140 (-14%) info
Market Cap: $45.723M info